MARKET WIREStock Titan • 2d ago
A live webcast on MediWound’s third-quarter results starts Nov. 12 at 8:30 a.m. ET.Stock Titan report covering MediWound Ltd. (MDWD) market action, institutional positioning, and fundamental catalysts.
Why MDWD Stock slipped -0.81% Today — RQD Quant Desk Flash
$13.39 -0.81% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $13.35
MediWound Ltd. (MDWD) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $174.3M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on MDWD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is MDWD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, MediWound Ltd. (NASDAQ: MDWD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $13.39 (-0.81% 1D, market cap $174.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, MDWD ranks #291 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does MDWD compare to NAGE and GLAS in the Health Care sector?
▼
Within the Health Care sector (Medicinal Chemicals and Botanical Products), MDWD carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NAGE (Niagen Bioscience Inc.) holds a D+ grade (57/100 RQD, P/E 11.4x, ROIC 16.8%, cap $189.9M) and GLAS (Glass House Brands Inc. Subordinate Voting Shares) posts a E grade (18/100 RQD, P/E N/A, ROIC -9.2%, cap $207.7M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while NAGE leads on capital efficiency (16.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for MDWD?
▼
For MediWound Ltd. (MDWD), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #291 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
🎯 MDWD TRADE EXECUTION LEVELS + TODAY'S TOP 3 TRADES
EXACT ENTRY • HARD STOP-LOSS (SUP) • TARGET (RES) • WHY
Where to Enter $MDWD, Where to Set Your Hard Stop-Loss & Today's Top 3 High-Conviction Trades
🏆 RECENT ALERT WINNERS:
$XYZ +15.6% (2d)
$PLTR +13.7% (4d)
$VRT +8.4% (2d)
CURRENT TICKER SETUP • $MDWD
R/R 2.2 : 1 • RQD 48/100 (D)
$MDWD
Spot $13.39 1. GET IN (ENTRY)
$13.31–$13.46
2. HARD STOP (SUP)
$12.69 (-5.2%)
3. GET OUT (T1/T2)
$14.26 / $14.93
STOP-LOSS FLOOR (SUP $12.69):
Hard stop sits 5.2% below spot to cap downside below key institutional support. If $MDWD closes a daily candle below $12.69, step aside.
PROFIT TARGETS (RES $14.26 / $14.93):
Scale out 50% at T1 (+6.5%) and trail stop to breakeven for T2 (+11.5%).
Want this $MDWD sheet + Today's Top 3 Trades emailed free?
Paper Trade $MDWD →
⚡ TODAY'S TOP 3 SUGGESTED TRADES OF THE DAY (100% FREE CHEAT SHEET)
Trade #1 Unlocked • Enter Email Below to Unblur #2 & #3 + Get $MDWD Sheet
#1 • $MU R/R 3.2 : 1
Micron Technology, Inc.
IN
$108.50
STOP
$103.90
OUT
$117.50
#2 • 🔒 LOCKED R/R 3.4 : 1
AI Liquid-Cooling Leader
Target: +8.53% to +14.86%
| Stop: -3.89%
#3 • 🔒 LOCKED R/R 3.1 : 1
Cash-Flow Buyback Machine
Target: +8.38% to +14.53%
| Stop: -3.93%
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $13.34 (-0.34%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw D · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-4.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MDWD)Realized 20D OHLCV Swing Band: ±9.1%
Deterministic 5-Pillar Attribution (48/100 Composite)
🔍 WHY MDWD SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (25% of score)
SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($4.9M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$11.91+1.6% Next Q
40
Q2 (-2Q)Grade D$12.10+12.1% Next Q
43
Q3 (-1Q)Grade D$13.56-1.3% Next Q
45
CurrentGrade D$13.39-5.6% Hist 90D α
48
Trajectory: D (40) → D (48)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a MDWD Turnaround Squeeze
While MDWD currently carries a cautious 48/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.09) and Max Pain ($14.06) forces dealer call-delta covering toward $20.68.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MDWD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MDWD Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MDWD Stock slipped -0.81% Today — RQD Quant Desk Flash
MediWound Ltd. (MDWD) slipped -0.81% to $13.39, trading at 20% of its 52-week range ($11.8 – $19.7). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 20% of its 52-week range ($11.8 – $19.7) with RSI-14 at 55.5 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.1% around $13.39 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $4.9M annual free cash flow.
Live MDWD Headlines & Catalysts
MARKET WIRESimply Wall St • 2d ago
Favourable Signals For MediWound: Numerous Insiders Acquired StockSimply Wall St report covering MediWound Ltd. (MDWD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGlobeNewswire • 2d ago
MediWound to Report Third Quarter 2026 Financial ResultsGlobeNewswire report covering MediWound Ltd. (MDWD) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Traders Daily • 2d ago
(MDWD) Risk Channels and Responsive AllocationStock Traders Daily report covering MediWound Ltd. (MDWD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 2d ago
Fennec Pharmaceuticals Inc. (FRX.TO) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering MediWound Ltd. (MDWD) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.siam.in/ • 2d ago
MediWound Ltd. (MDWD) Jumps 5.66% to $13.26 as Buyers Test Upper Resistance - Gamma Squeezehttps://www.siam.in/ report covering MediWound Ltd. (MDWD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 1d ago
MediWound Announces $15 Million Bought Deal Offering of Ordinary SharesMediWound Announces $15 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 3, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a global leader in next-generation enzymatic therape
CATALYSTYahoo • 1d ago
Madrigal (MDGL) Q3 Earnings and Revenues Beat EstimatesMadrigal (MDGL) delivered earnings and revenue surprises of +267.89% and +7.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
MARKET WIREBenzinga • 1d ago
MediWound Announces $15M Bought Deal Offering Of 1.2M Shares At $12.50/ShareThe closing of the offering is expected to occur on or about November 5, 2026, subject to satisfaction of customary closing conditions.H.C. Wainwright & Co. is acting as the sole book-running manager for the
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MDWD)
- ✓Walkthrough of MDWD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MDWD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.22%📐 HORIZONTAL RANGE
2026-11-04O $13.30H $13.50L $13.30C $13.39VOL 120.4K
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MDWD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on MDWD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MDWD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MDWD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MDWD)
Health Care Rank #291 of 1015
⚔️ NAGE vs MDWD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MDWD vs. NAGE, GLAS, ACB, USNA)
Industry: Medicinal Chemicals and Botanical Products (23 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, MediWound Ltd. (MDWD) ranks #291 by composite RQD confidence (48/100, grade D) and #589 by equity capitalization ($174.3M). Within this direct 5-issuer industry benchmark cohort, NAGE leads on earnings valuation at 11.4x trailing P/E, while NAGE leads on capital efficiency and profitability with 16.8% ROIC and 64.3% gross margin. NAGE currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with MDWD at 48/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MDWD
ACTIVE
MediWound Ltd. | D | 48/100 | — | — | — | -0.81% | $174.3M | Benchmark Subject |
| NAGE Niagen Bioscience Inc. | D+ | 57/100 | 11.4x | 64.3% | 16.8% | -1.67% | $189.9M | /nage-vs-mdwd → |
| GLAS Glass House Brands Inc. Subordinate Voting Shares | E | 18/100 | — | 42.3% | -9.2% | -0.85% | $207.7M | /glas-vs-mdwd → |
| ACB Aurora Cannabis Inc. | D+ | 54/100 | — | — | — | +22.28% | $261.5M | /acb-vs-mdwd → |
| USNA USANA Health Sciences Inc. | D | 50/100 | 24.6x | 78.3% | 7.9% | +1.02% | $272.0M | /usna-vs-mdwd → |
2. MDWD Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTMediWound Ltd. (MDWD) operates in Medicinal Chemicals and Botanical Products (Health Care) with an equity capitalization of $174.3M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. MDWD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MDWD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, MediWound Ltd. (NASDAQ: MDWD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $13.39 (-0.81% 1D, market cap $174.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, MDWD ranks #291 in composite RQD confidence.
How does MDWD compare to NAGE and GLAS in the Health Care sector?
Within the Health Care sector (Medicinal Chemicals and Botanical Products), MDWD carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NAGE (Niagen Bioscience Inc.) holds a D+ grade (57/100 RQD, P/E 11.4x, ROIC 16.8%, cap $189.9M) and GLAS (Glass House Brands Inc. Subordinate Voting Shares) posts a E grade (18/100 RQD, P/E N/A, ROIC -9.2%, cap $207.7M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while NAGE leads on capital efficiency (16.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MDWD?
For MediWound Ltd. (MDWD), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #291 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MDWD trading relative to its 50-day, 200-day, and 52-week technical levels?
MDWD last traded at $13.39 (-0.81% on volume of 89,863 shares), positioning the stock +2.29% above its 50-day simple moving average ($13.09) and -11.85% below its 200-day simple moving average ($15.19). Across its 52-week range of $11.80 to $19.70, MDWD sits at the 20.1% percentile with a 14-day RSI of 55.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.1% ($12.17 to $14.61).
ROARABLE RATING BRIEF • RQD 48/100 (D)
✓ SEC XBRL & RQD VERIFIED
MDWD — MediWound Ltd.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03
1. Roarable Rating Brief: What This Means to a Prospective Investor
MediWound Ltd. (MDWD) earns a live Roarable RQD composite score of 48/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $13.39 (-0.81% 1D, market capitalization $174.3M).
- Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (6/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
MediWound Ltd. (MDWD) is a NASDAQ-listed issuer in the Health Care sector, classified under the Medicinal Chemicals and Botanical Products industry,..2B. — describes its specific products, customers, or revenue model.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 48/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $11.80 – $19.70 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
A prospective investor should note that the absence of mapped dependencies means ripple effects from suppliers, customers, or peers cannot be assessed from this dataset.
- Key Question #1: Can MDWD sustain or expand its — operating margin and — ROIC against Medicinal Chemicals and Botanical Products peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $19.70 52-week high?
- Key Question #3: How sensitive is MDWD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
MDWD Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for MediWound Ltd. (MDWD) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Stock Titan • 2d ago
A live webcast on MediWound’s third-quarter results starts Nov. 12 at 8:30 a.m. ET. Stock Titan report covering MediWound Ltd. (MDWD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 2d ago
Favourable Signals For MediWound: Numerous Insiders Acquired Stock Simply Wall St report covering MediWound Ltd. (MDWD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 2d ago
MediWound to Report Third Quarter 2026 Financial Results GlobeNewswire report covering MediWound Ltd. (MDWD) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Traders Daily • 2d ago
(MDWD) Risk Channels and Responsive Allocation Stock Traders Daily report covering MediWound Ltd. (MDWD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 2d ago
Fennec Pharmaceuticals Inc. (FRX.TO) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering MediWound Ltd. (MDWD) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.siam.in/ • 2d ago
MediWound Ltd. (MDWD) Jumps 5.66% to $13.26 as Buyers Test Upper Resistance - Gamma Squeeze https://www.siam.in/ report covering MediWound Ltd. (MDWD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 1d ago
MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 3, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a global leader in next-generation enzymatic therape
🟢 CATALYST Yahoo • 1d ago
Madrigal (MDGL) Q3 Earnings and Revenues Beat Estimates Madrigal (MDGL) delivered earnings and revenue surprises of +267.89% and +7.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
MDWD Bull vs. Bear Conversation Board — What's Your Call at $13.39?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MDWD 🐻 33% BEARISH CONVICTION
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH
🎯 Target: $16.49 (+24.0%)
📌 Pinned Debate The Forensic Balance Sheet pillar (13/20) with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5 is the strongest component of the rat
Here is why I am bullish on MDWD here at $13.30: The Forensic Balance Sheet pillar (13/20) with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5 is the strongest component of the rating.. Compare MDWD's 0.0% operating margin and 0.0% ROIC against the rest of Medicinal Chemicals and Botanical Products. As long as cash conversion holds up, dips toward $12.63 are getting bought.
EarningsSniper 🐂 BULL
Both sides have a point here — MDWD's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH
🎯 Target: $10.37 (-22.0%)
Spot @ $13.30 The RQD rating shows 0% ROIC and 0% FCF yield, with Fundamental Cash Engine at 12/20 and Macro Regime Fit at 8/20.
I respect the product at MediWound Ltd., but the stock at $13.30 is a different story. The RQD rating shows 0% ROIC and 0% FCF yield, with Fundamental Cash Engine at 12/20 and Macro Regime Fit at 8/20.. FCF yield is 0.0% and RQD sits at 48/100 (D) — why pay up here when you can wait for next quarter's numbers?